Aims: The influence of lifestyle-related factors, including smoking and drinking, was evaluated for Helicobacter pylori eradication therapy with vonoprazan or proton pump inhibitors (PPIs). Methods: Between 2012 and 2016, the medical records of 620 patients receiving H. pylori eradication therapy at Saiseikai Karatsu Hospital were evaluated. Patients had received vonoprazan (20 mg) or PPIs with 200 mg clarithromycin and 750 mg amoxicillin twice daily for 7 days. The influence of lifestyle-related factors on eradication failure was determined in the 2 groups. Results: The eradication rates for vonoprazan and lansoprazole, rabeprazole, and esomeprazole were, respectively, 91.0, 73.8, 72.0, and 84.6%. The vonoprazan eradication rate was significantly higher than those for the PPIs (p < 0.01). Habitual smoking and drinking did not increase eradication failure, and smoking and drinking during the eradication period did not reduce the eradication rate. Metabolic syndrome-related factors including obesity, hypertension, and diabetes mellitus had no negative influence on the eradication rate. Eradication with vonoprazan was more effective compared with that achieved through the use of PPIs. Conclusion: Lifestyle-related factors including smoking and drinking did not exacerbate the H. pylori eradication failure, and vonoprazan was more effective than the PPIs.

1.
Mahachai V, Vilaichone RK, Pittayanon R, Rojborwonwitaya J, Leelakusolvong S, Maneerattanaporn M, Chotivitayatarakorn P, Treeprasertsuk S, Kositchaiwat C, Pisespongsa P, Mairiang P, Rani A, Leow A, Mya SM, Lee YC, Vannarath S, Rasachak B, Chakravuth O, Aung MM, Ang TL, Sollano JD, Trong Quach D, Sansak I, Wiwattanachang O, Harnsomburana P, Syam AF, Yamaoka Y, Fock KM, Goh KL, Sugano K, Graham D: Helicobacter pylori management in ASEAN: the Bangkok consensus report. J Gastroenterol Hepatol 2018; 33: 37–56.
2.
Ansari S, Yamaoka Y: Survival of Helicobacter pylori in gastric acidic territory. Helicobacter 2017; 22.
3.
Camilo V, Sugiyama T, Touati E: Pathogenesis of Helicobacter pylori infection. Helicobacter 2017; 22(suppl 1).
4.
Matsuzaki J, Hayashi R, Arakawa T, Ueno F, Kinoshita Y, Joh T, Takahashi S, Naito Y, Fukudo S, Chan FK, Hahm KB, Kachintorn U, Fock KM, Syam AF, Rani AA, Sollano JD, Zhu Q, Fujiwara Y, Kubota E, Kataoka H, Tokunaga K, Uchiyama K, Suzuki H: Questionnaire-based survey on diagnostic and therapeutic endoscopies and H. pylori eradication for elderly patients in East Asian countries. Digestion 2016; 93: 93–102.
5.
Lender N, Talley NJ, Enck P, Haag S, Zipfel S, Morrison M, Holtmann GJ: Associations between Helicobacter pylori and obesity – an ecological study. Aliment Pharmacol Ther 2014; 40: 24–31.
6.
Takeshita E, Sakata Y, Hara M, Akutagawa K, Sakata N, Endo H, Ohyama T, Matsunaga K, Yoshioka T, Kawakubo H, Tanaka Y, Shirai S, Ito Y, Tsuruoka N, Iwakiri R, Kusano M, Fujimoto K: Higher frequency of reflux symptoms and acid-related dyspepsia in women than men regardless of endoscopic esophagitis: analysis of 3,505 Japanese subjects undergoing medical health checkups. Digestion 2016; 93: 266–271.
7.
Tanaka Y, Sakata Y, Hara M, Kawakubo H, Tsuruoka N, Yamamoto K, Itoh Y, Hidaka H, Shimoda R, Iwakiri R, Fujimoto K: Risk factors for Helicobacter pylori infection and endoscopic reflux esophagitis in healthy young Japanese volunteers. Intern Med 2017; 56: 2979–2983.
8.
Suzuki H, Mori H: World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. J Gastroenterol 2018; 53: 354–361.
9.
Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM: Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017; 66: 6–30.
10.
Fujishiro M, Iguchi M, Kakushima N, Kato M, Sakata Y, Hoteya S, Kataoka M, Shimaoka S, Yahagi N, Fujimoto K: Guidelines for endoscopic management of non-variceal upper gastrointestinal bleeding. Dig Endosc 2016; 28: 363–378.
11.
Miftahussurur M, Yamaoka Y: Diagnostic methods of Helicobacter pylori infection for epidemiological studies: critical importance of indirect test validation. Biomed Res Int 2016; 2016: 4819423.
12.
Asaka M, Mabe K, Matsushima R, Tsuda M: Helicobacter pylori eradication to eliminate gastric cancer: the Japanese strategy. Gastroenterol Clin North Am 2015; 44: 639–648.
13.
European Helicobacter Pylori Study Group: Current European concepts in the management of Helicobacter pylori infection. The Maastricht consensus report. Gut 1997; 41: 8–13.
14.
Peura DA: The report of the digestive health Initiative international update conference on Helicobacter pylori. Gastroenterology 1997; 113:S4–S8.
15.
Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA: The global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 2016; 43: 514–533.
16.
Noda H, Noguchi S, Yoshimine T, Goji S, Adachi K, Tamura Y, Izawa S, Ebi M, Yamamoto S, Ogasawara N, Funaki Y, Sasaki M, Kasugai K: A novel potassium-competitive acid blocker improves the efficacy of clarithromycin-containing 7-day triple therapy against Helicobacter pylori. J Gastrointest Liver Dis 2016; 25: 283–288.
17.
Isomoto H, Furusu H, Morikawa T, Mizuta Y, Nishiyama T, Omagari K, Murase K, Inoue K, Murata I, Kohno S: 5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication. Aliment Pharamacol Ther 2000; 14: 1619–1623.
18.
Ogura K, Yoshida H, Maeda S, Yamaji Y, Kawabe T, Okamoto M, Shiratori Y, Omata M: Clarithromycin-based triple therapy for non-resistant Helicobacter pylori infection. How long should it be given? Scand J Gastroenterol 2001; 36: 584–588.
19.
Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Uotani T, Ikuma M, Shirai N: The dual therapy with 4 times daily dosing of rabeprazole and amoxicillin as the 3rd rescue regimen for eradication of H. pylori. Hepatogastroenterology 2010; 57: 1314–1319.
20.
Furuta T, Graham DY: Pharmacologic aspects of eradication therapy for Helicobacter pylori infection. Gastroenterol Clin North Am 2010; 39: 465–480.
21.
Andersson K, Carlsson E: Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther 2005; 108: 294–307.
22.
Jenkins H, Sakurai Y, Nishimura A, Okamoto H, Hibberd M, Jenkins R, Yoneyama T, Ashida K, Ogama Y, Warrington S: Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment pharmacol Ther 2015; 4: 636–648.
23.
Echizen H: The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 2016; 55: 409–418.
24.
Otake K, Sakurai Y, Nishida H, Fukui H, Tagawa Y, Yamasaki H, Karashima M, Otsuka K, Inatomi N: Characteristics of the novel potassium-competitive acid blocker vonoprazan fumarate (TAK-438). Adv Ther 2016; 33: 1140–1157.
25.
Sue S, Kuwashima H, Iwata Y, Oka H, Arima I, Fukuchi T, Sanga K, Inokuchi Y, Ishii Y, Kanno M, Terada M, Amano H, Naito M, Iwase S, Okazaki H, Komatsu K, Kokawa I, Kawana I, Morimoto M, Saito T, Kunishi Y, Ikeda A, Takahashi D, Miwa H, Sasaki T, Tamura T, Kondo M, Shibata W, Maeda S: The Superiority of vonoprazan-based first-line triple therapy with clarithromycin: a prospective multi-center cohort study onHelicobacter pylori eradication. Intern Med 2017; 56: 1277–1285.
26.
Jung YS, Kim EH, Park CH: Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther 2017; 46: 106–114.
27.
Shichijo S, Hirata Y, Niikura R, Hayakawa Y, Yamada A, Mochizuki S, Matuo K, Isomura Y, Seto M, Suzuki N, Suzuki H, Yamamoto S, Sugimoto T, Omae T, Okamoto M,  Watabe H, Togo G, Takano N, Fukui K, Ito Y, Koike K: Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: a multicenter retrospective study in clinical practice. J Dig Dis 2016; 17: 670–675.
28.
Matsumoto H, Shiotani A, Katsumata R, Fujita M, Nakato R, Murao T, Ishii M, Kamada T, Haruma K, Graham DY: Helicobacter pylori eradication with proton pump inhibitors or potassium-competitive acid blockers: the effect of clarithromycin resistance. Dig Dis Sci 2016; 61: 3215–3220.
29.
Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M: Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 2016; 65: 1439–1446.
30.
Suzuki S, Gotoda T, Kusano C, Iwatsuka K, Moriyama M: The Efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker compared with a 7-day PPI-based low dose clarithromycin triple therapy. Am J Gastroenterol 2016: 111: 949–956.
31.
Sakurai K, Suda H, Ido Y, Takeichi T, Okuda A, Hasuda K, Hattori M: Comparative study: vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy. World J Gastroenterol 2017; 23: 668–675.
32.
Maruyama M, Tanaka N, Kubota D, Miyajima M, Kimura T, Tokutake K, Imai R, Fujisawa T, Mori H, Matsuda Y, Wada S, Horiuchi A, Kiyosawa K: Vonoprazan-based regimen is more useful than PPI-based one as a first-line Helicobacter pylori eradication: a randomized control trial. Can J Gastroenterol Hepatol: 2017; 2017: 4385161.
33.
Tsujimae M, Yamashita H, Hashimura H, Kano C, Shimoyama K, Kanamori A, Matsumoto K, Koizumi A, Momose K, Eguchi T, Fukuchi T, Fujita M, Okada A: A comparative study of a new class of gastric acid suppressant agent named vonoprazan versus esomeprazole for the eradication of Helicobacter pylori. Digestion 2016; 94: 240–246.
34.
Shinozaki S, Nomoto H, Kondo Y, Sakamoto H, Hayashi Y, Yamamoto H, Lefor AK, Osawa H: Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori. Kaohsiung J Med Sci 2016; 32: 255–260.
35.
Yamada S, Kawakami T, Nakatsugawa Y, Suzuki T, Fujii H, Tomatsuri N, Nakamura H, Sato H, Okuyama Y, Kimura H, Yoshida N: Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori. World J Gastrointest Pharmacol Ther 2016; 7: 550–555.
36.
Ozaki H, Harada S, Takeuchi T, Kawaguchi  S, Takahashi Y, Kojima Y, Ota K, Hongo Y, Ashida K, Sakaguchi M, Tokioka S, Sakamoto H, Furuta T, Tominaga K, Higuchi K: Vonoprazan, a novel potassium-competitive acid blocker, should be used for the Helicobacter pylori eradication therapy as first choice: a large sample study of vonoprazan in real world compared with our randomized control trial using second-generation proton pump inhibitors for Helicobacter pylori eradication therapy. Digestion. 2018; 97: 212–218.
37.
Chey WD, Leontiadis GI, Howden CW, Moss SF: ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol 2017; 112: 212–239.
38.
Lanas A, Hirschowitz BI: Influence of smoking on basal and on vagally and maximally  stimulated gastric acid and pepsin secretion. Scand J Gastroenterol 1992; 27: 208–212.
39.
Suzuki T, Matsuo K, Ito H, Sawaki A, Hirose K, Wakai K, Sato S, Nakamura T, Yamao K, Ueda R, Tajima K: Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med 2006; 119: 217–224.
40.
Itskoviz D, Boltin D, Leibovitzh H, Tsadok Perets T, Comaneshter D, Cohen A, Niv Y, Levi Z: Smoking increases the likelihood of Helicobacter pylori treatment failure. Dig Liver Dis 2017; 49: 764–768.
41.
Furuta T, Sugimoto M, Yamade M, Uotani T, Sahara S, Ichikawa H, Yamada T, Osawa S, Sugimoto K, Watanabe H, Umemura K: Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy. J Clin Pharmacol 2014; 54: 258–266.
42.
Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T: Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharcacokinet 2005; 20: 153–167.
43.
Murakami K, Furuta T, Ando T, Nakajima T, Inui Y, Oshima T, Tomita T, Mabe K, Sasaki M, Suganuma T, Nomura H, Satoh K, Hori S, Inoue S, Tomokane T, Kudo M, Inaba T, Take S, Ohkusa T, Yamamoto S, Mizuno S, Kamoshida T, Amagai K, Iwamoto J, Miwa J, Kodama M, Okimoto T, Kato M, Asaka M; Japan GAST Study Group: Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan. J Gastroenterol. 2013; 48: 1128–1135.
44.
Takahashi Y, Takeuchi T, Kojima Y, Nagami Y, Ominami M, Uedo N, Hamada K, Suzuki H, Oda I, Miyaoka Y, Yamanouchi S, Tokioka S, Tomatsuri N, Yoshida N, Naito Y, Nonaka T, Kodashima S, Ogata S, Hongo Y, Oshima T, Li Z, Shibagaki K, Oikawa T, Tominaga K, Higuchi K: Efficacy and safety of Helicobacter pylori eradication therapy immediately after endoscopic submucosal dissection. J Gastroenterol Hepatol 2017, Epub ahead of print.
45.
Graham DY, Shiotani A: New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 321–331.
46.
Horikawa C, Kodama S, Fujihara K, Hirasawa R, Yachi Y, Suzuki A, Hanyu O, Shimano H, Sone H: High risk of failing eradication of Helicobacter pylori in patients with diabetes: a meta-analysis: Diabetes Res Clin Pract 2014; 106: 81–87.
47.
Yoshioka T, Takeshita E, Sakata Y, Hara M, Akutagawa K, Sakata N, Endo H, Ohyama T, Matsunaga K, Tanaka Y, Shirai S, Ito Y, Tsuruoka N, Iwakiri R, Kusano M, Fujimoto K: Helicobacter pylori infection status had no influence on upper gastrointestinal symptoms: a cross-sectional analysis of 3,005 Japanese subjects without upper gastrointestinal lesions undergoing medical health checkups. Esophagus. 2017; 14: 249–253.
48.
Kato M (ed): The Japanese Society for ­Helicobacter Research: Guidelines for diagnosis and therapy of Helicobacter pylori infection. Sentaniryo-sha, Tokyo, 2016 (in Japanese).
49.
Matsuura S, Sakata Y, Tsuruoka N, Miyahara K, Hara M, Ito Y, Nakayama K, Shimamura T, Noda T, Yukimoto T, Shimoda R, Iwakiri R, Fujimoto K: Outcomes of patients undergoing endoscopic hemostasis for the upper gastrointestinal bleeding were not influenced by the timing of hospital emergency visits: a situation prevailing in Japan. Digestion 2018; 97: 260–266.
You do not currently have access to this content.